Docmode Health

  • Market Cap: Micro Cap
  • Industry: Hospital
  • ISIN: INE0OGG01015
  • NSEID: DHTL
  • BSEID:
INR
59.00
-3.1 (-4.99%)
BSENSE

Dec 17

BSE+NSE Vol: 4800

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

4.8 k (66.67%) Volume

Shareholding (Sep 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

30.86%

When is the next results date for Docmode Health?

06-Jun-2025

No Upcoming Board Meetings

Has Docmode Health declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Docmode Health?

04-Jun-2025

Docmode Health's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institu, Rainbow Child, Dr Agarwal's Health, and Broach. Max Healthcare and Apollo Hospitals show excellent growth and management, while Docmode Health has a 1-year return of 0.00%.

Peers: The peers of Docmode Health are Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institu, Rainbow Child, Dr Agarwal's Hea, and Broach.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Krishna Institu, Rainbow Child, and Dr Agarwal's Hea, while Average management risk is found at Fortis Health, Aster DM Health, and Broach. Growth is excellent at Max Healthcare and Apollo Hospitals, good at Fortis Health, Narayana Hrudaya, and Dr Agarwal's Hea, while below average growth is noted at Aster DM Health, Krishna Institu, Rainbow Child, and Broach. Capital structure is excellent at Max Healthcare, Global Health, and Krishna Institu, good at Fortis Health, Narayana Hrudaya, Rainbow Child, and Broach, while below average capital structure is seen at Aster DM Health, Docmode Health, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krishna Institu at 85.24%, while the lowest is Dr Agarwal's Hea and Broach, both with N/A returns, and Docmode Health's own 1-year return is 0.00%. Additionally, Aster DM Health and Broach have negative six-month returns.

Read More

Is Docmode Health overvalued or undervalued?

09-Jun-2025

As of June 2, 2025, Docmode Health is classified as risky and overvalued, with a PE ratio of -10.42 and a year-to-date return of -23.83%, significantly underperforming compared to its peers and the Sensex.

As of 2 June 2025, the valuation grade for Docmode Health has moved from does not qualify to risky. The company is currently assessed as overvalued. Key ratios indicate significant financial distress, with a PE ratio of -10.42, an EV to EBIT of -27.08, and a ROE of -19.55%. <BR><BR>In comparison to its peers, Docmode Health's valuation metrics are starkly unfavorable; for instance, Veranda Learning, also classified as risky, has a PE ratio of 165.27, while Shanti Educational Initiatives Ltd. is deemed very expensive with a PE ratio of 199.65. The recent stock performance shows a significant decline, with a year-to-date return of -23.83%, contrasting sharply with the Sensex's gain of 6.24% during the same period, further reinforcing the overvaluation narrative.

Read More

What is the technical trend for Docmode Health?

09-Jun-2025

As of June 2, 2025, Docmode Health's trend has shifted to mildly bearish due to daily moving averages indicating bearish momentum, despite some underlying strength from weekly MACD and a neutral outlook from Dow Theory.

As of 2 June 2025, the technical trend for Docmode Health has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating bearish momentum. The weekly MACD remains mildly bullish, suggesting some underlying strength, but the overall trend is tempered by the daily indicators. The RSI shows no signal across both weekly and monthly time frames, indicating a lack of momentum. Additionally, the Dow Theory shows no trend in both weekly and monthly perspectives, further supporting a neutral outlook. Overall, while there are some bullish signals in the weekly indicators, the prevailing daily bearish trend suggests caution.

Read More

What does Docmode Health do?

17-Jul-2025

Docmode Health Technologies Ltd is a micro-cap company in the hospital industry, incorporated in 2017 and converted to a public limited company in 2023. It currently has no reported sales or profits, with a market cap of INR 15 Cr.

Overview: <BR>Docmode Health Technologies Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Docmode Health Technologies Ltd was incorporated on July 17, 2017, and was initially registered as a private limited company. It later converted to a public limited company, with the name change taking effect on January 2, 2023. There is no recent sales or profit data reported.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 15 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 43 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.57 <BR>Return on Equity: -19.55% <BR>Price-to-Book: 1.41 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Read More

Who are the top shareholders of the Docmode Health?

17-Jul-2025

The top shareholders of Docmode Health include Paulson Paul Thazhathedath, who holds 23.71%, and individual investors who collectively own 48.97%. There are no mutual funds or foreign institutional investors involved, and pledged promoter holdings are at 61.1641%.

The top shareholders of Docmode Health primarily consist of non-institutional investors. The promoter with the highest holding is Paulson Paul Thazhathedath, who owns 23.71% of the company. Additionally, individual investors collectively hold 48.97% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company. The pledged promoter holdings stand at 61.1641%.

Read More

How big is Docmode Health?

24-Jul-2025

As of 23rd July, Docmode Health Technologies Ltd has a market capitalization of 16.00 Cr, classified as a Micro Cap, with no available financial data for Net Sales or Net Profit for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds of 10.37 Cr and Total Assets of 26.21 Cr.

As of 23rd July, <BR><BR>Market Cap: Docmode Health Technologies Ltd has a market capitalization of 16.00 Cr, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 10.37 Cr and Total Assets valued at 26.21 Cr.

Read More

How has been the historical performance of Docmode Health?

03-Dec-2025

Docmode Health has experienced significant sales growth from 12.42 Cr in March 2022 to 41.77 Cr in March 2025, but rising expenditures have led to negative operating profit and losses in profit before and after tax, with EPS dropping to -6.46. Total assets and liabilities have increased to 39.06 Cr by March 2025, while cash flow remains tight.

Answer:<BR>The historical performance of Docmode Health shows a fluctuating trend in key financial metrics over the past four fiscal years.<BR><BR>Breakdown:<BR>Docmode Health's net sales have increased from 12.42 Cr in March 2022 to 41.77 Cr in March 2025, indicating a strong growth trajectory. However, the total expenditure has also risen significantly, from 10.54 Cr in March 2022 to 42.45 Cr in March 2025, leading to an operating profit (PBDIT) that turned negative at -0.68 Cr in March 2025, down from a positive 3.75 Cr in March 2023. Consequently, the profit before tax has declined sharply to -1.97 Cr in March 2025, compared to 2.69 Cr in March 2023. The profit after tax mirrored this decline, falling to -2.03 Cr in March 2025 from 1.95 Cr in March 2023. The company's earnings per share (EPS) also reflect this downturn, dropping to -6.46 in March 2025 from 8.52 in March 2023. On the balance sheet, total assets have increased from 10.01 Cr in March 2022 to 39.06 Cr in March 2025, while total liabilities have also risen from 10.01 Cr to 39.06 Cr in the same period. Cash flow from operating activities improved to 4.00 Cr in March 2024, but the overall cash flow situation remains tight with a closing cash equivalent of 3.00 Cr in March 2024.

Read More

Why is Docmode Health falling/rising?

17-Dec-2025

As of 16-Dec, Docmode Health Technologies Ltd's stock price is at 62.10, down 4.97%, with significant declines over the past week (14.34%) and month (43.52%). The stock is underperforming against the Sensex and is trading below all moving averages, indicating a bearish trend and liquidity issues.

As of 16-Dec, Docmode Health Technologies Ltd's stock price is falling, currently at 62.10, reflecting a decrease of 3.25 or 4.97%. This decline is evident in the stock's performance over various periods, with a significant drop of 14.34% over the past week and a staggering 43.52% over the last month. Year-to-date, the stock has decreased by 29.71%, while it has fallen by 39.06% over the past year. <BR><BR>Additionally, the stock is underperforming compared to the benchmark Sensex, which has shown a slight increase of 0.08% over the past week and a positive return of 9.37% year-to-date. The performance today indicates that Docmode Health has underperformed its sector by 4.68%. <BR><BR>The stock is also trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend. Furthermore, there has been a notable decline in investor participation, with a delivery volume of 0 on December 15, indicating a 100% drop against the 5-day average delivery volume. This lack of trading activity contributes to the stock's liquidity issues, as it is only liquid enough for a trade size of Rs 0 crore based on 2% of the 5-day average traded value. All these factors collectively explain the ongoing decline in Docmode Health's stock price.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Hospital

stock-summary
Market cap

INR 20 Cr (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

45

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.59

stock-summary
Return on Equity

-24.30%

stock-summary
Price to Book

2.34

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
29.24%
0%
29.24%
6 Months
-3.04%
0%
-3.04%
1 Year
-42.1%
0%
-42.1%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Docmode Health for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News

How has been the historical performance of Docmode Health?

Revenue and Operating Performance

Docmode Health’s net sales have shown a robust upward trend, rising from ₹12.42 crores in March 2022 to ₹41.77 crores by March 2025. This growth reflects a more than threefold increase over three years, signalling expanding market presence and sales traction. Total operating income mirrored this trend, with no other operating income reported during this period.

However, the company’s expenditure profile reveals some challenges. While raw material costs were nil, the purchase of finished goods surged dramatically to ₹44.77 crores in March 2025 from just ₹1.05 crores in March 2022, indicating a shift in procurement or inventory strategy. Employee costs have slightly decreased from ₹5.56 crores in March 2023 to ₹3.76 crores in March 2025,...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
12.70%
EBIT Growth (5y)
-151.52%
EBIT to Interest (avg)
1.30
Debt to EBITDA (avg)
1.96
Net Debt to Equity (avg)
0.59
Sales to Capital Employed (avg)
3.14
Tax Ratio
3.05%
Dividend Payout Ratio
0
Pledged Shares
40.30%
Institutional Holding
0
ROCE (avg)
46.06%
ROE (avg)
19.29%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
0
Price to Book Value
2.22
EV to EBIT
-23.49
EV to EBITDA
-23.49
EV to Capital Employed
1.77
EV to Sales
0.56
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-7.44%
ROE (Latest)
-24.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

40.3002

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Paulson Paul Thazhathedath (17.78%)

Highest Public shareholder

Bindi Kunal Mehta (16.58%)

Individual Investors Holdings

64.71%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Docmode Health"
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Mar 2025 is 4.55% vs 24.51% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Mar 2025 is -165.38% vs 55.56% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "21.35",
          "val2": "20.42",
          "chgp": "4.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.56",
          "val2": "-0.12",
          "chgp": "-366.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.83",
          "val2": "1.09",
          "chgp": "-23.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.38",
          "val2": "-0.52",
          "chgp": "-165.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2.62%",
          "val2": "-0.59%",
          "chgp": "-2.03%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Docmode Health"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 4.40% vs 21.68% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -1,168.42% vs -90.26% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "41.77",
          "val2": "40.01",
          "chgp": "4.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.68",
          "val2": "1.88",
          "chgp": "-136.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.92",
          "val2": "1.66",
          "chgp": "15.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.03",
          "val2": "0.19",
          "chgp": "-1,168.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1.63%",
          "val2": "4.70%",
          "chgp": "-6.33%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Half Yearly Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Sep'24
Change(%)
Net Sales
21.35
20.42
4.55%
Operating Profit (PBDIT) excl Other Income
-0.56
-0.12
-366.67%
Interest
0.83
1.09
-23.85%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.38
-0.52
-165.38%
Operating Profit Margin (Excl OI)
-2.62%
-0.59%
-2.03%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Mar 2025 is 4.55% vs 24.51% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Mar 2025 is -165.38% vs 55.56% in Sep 2024

Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
41.77
40.01
4.40%
Operating Profit (PBDIT) excl Other Income
-0.68
1.88
-136.17%
Interest
1.92
1.66
15.66%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.03
0.19
-1,168.42%
Operating Profit Margin (Excl OI)
-1.63%
4.70%
-6.33%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 4.40% vs 21.68% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -1,168.42% vs -90.26% in Mar 2024

stock-summaryCompany CV
About Docmode Health Technologies Ltd stock-summary
stock-summary
Docmode Health Technologies Ltd
Micro Cap
Hospital
Docmode Health Technologies Limited was incorporated on July 17, 2017 as a private limited Company with the Deputy Registrar of Companies Mumbai. Thereafter, the Company was converted into a Public Limited Company and through effect in conversion of legal status dated January 2, 2023. DocMode is a pioneering healthcare technology company that is transforming the landscape of medical education, research, and practice.
Company Coordinates stock-summary
Icon
No Company Details Available